NCT00845650已完成1 期
A Randomized, Double-Blind, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 129
- 试验地点
- 2
- 主要终点
- Number of Participants Reporting Adverse Events (AEs)
研究概览
简要总结
The purpose of this study is to:
- evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) as compared with either 90 mg/kg, 180 mg/kg or 360 mg/kg total IgG, GAMUNEX® (immune globulin intravenous (human) 10% caprylate/chromatography purified). GAMUNEX is a trademark of Talecris Biotherapeutics.
- evaluate the pharmacokinetic (PK) profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) as measured by lethal toxin neutralizing antibody (TNA).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Between 18 and 65 years of age, inclusive.
- •Have a minimal weight of 110 lbs and a body mass index (BMI) between 17 and
- •In good health.
- •For pre-menopausal female subjects, using acceptable methods of birth control.
- •Willing and capable of complying with all aspects of the protocol through completion of the program period.
- •No blood donation in the preceding 8 weeks; willing to not donate whole blood or plasma during the clinical trial; and willing to not donate whole blood or plasma for up to one year following the last infusion.
- •Has read and signed an informed consent form.
- •Adequate venous access and can receive intravenous infusion.
排除标准
- •Previously intolerant of immune globulin or blood product preparations or known immunodeficiency.
- •Previous treatment with immune globulin products or blood products within three months of study.
- •Previous receipt of anthrax vaccine, known exposure to anthrax organisms, or previously enlisted in the military.
- •Receipt of any live vaccine within three months or inactivated vaccine within 2 weeks prior to study; plans to receive any vaccine at any time during the study.
- •Participation in any investigational clinical trial within one month prior to study.
- •Positive serology for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus.
- •Receipt of chemotherapy, radiation therapy, immunosuppressive therapy, or high-dose corticosteroid therapy within five years of study.
- •Use of prohibited medications as defined in the protocol.
- •History of drug or alcohol abuse within 1 year of study.
- •History of IgA deficiency.
- •Pregnancy.
- •Positive Coombs test at screening.
- •Males with a hemoglobin value less than 13.2 gm/dL and females less than 10.9 gm/dL.
- •Absolute eosinophil counts greater than 600 cells/mm3 or Absolute lymphocyte counts less than 1000 cells/mm
- •Aspartate aminotransferase (AST) >55 U/L or alanine aminotransferase (ALT) >60 U/L.
- •Hyperglycemia with random blood glucose >141 mg/dL, fasting blood glucose >112 mg/dL, or urine glucose >50 mg/dL; or hypoglycemia with a blood glucose <65 mg/dL.
- •BUN >25 mg/dL or creatinine, for males >1.4 mg/dL and, for females >1.2 mg/dL.
- •Creatinine clearance <80 mL/min.
- •Urine protein >15 mg/dL for males and non-menstruating females, or >30 mg/dL for menstruating females.
- •Febrile illness within three days prior to infusion.
- •History of significant medical or psychiatric condition or abnormal laboratory tests indicating possible underlying medical condition.
- •An opinion of the investigator that a condition exists that would preclude compliance with protocol-specified procedures.
- •Absolute neutrophil count is less than 3000 cells/mm3 as defined by the central lab (screening) or local lab (pre-infusion) for cohort B. Absolute neutrophil count is less than 2500 cells/mm3 as defined by the central lab (screening) or local lab (pre-infusion) for cohort C.
- •White blood cell counts are less than 3500 cells/mm3 as defined by the central lab (screening) or local lab (pre-infusion) for cohorts B and C.
- •History of a severe or anaphylactic reaction to quinolone or penicillin antibiotics.
结局指标
主要结局
Number of Participants Reporting Adverse Events (AEs)
时间窗: From the time of infusion through Day 90.
Any untoward medical occurrence reported to or observed by the principal investigator (PI), including as identified from other safety assessments (eg, vital signs, clinical laboratory testing, electrocardiogram).
次要结局
- Area Under the Curve to the Last Time With a Measurable TNA Titer (AUC[0-t])(From the time of infusion through Day 90 postinfusion.)
- Time of Cmax(From the time of infusion through Day 90 postinfusion.)
- Mean Residence Time (MRT)(From the time of infusion through Day 90 postinfusion.)
- Elimination Half-life (t½)(From the time of infusion through Day 90 postinfusion.)
- Maximum Plasma Titer/Concentration of TNA (Toxin Neutralizing Antibody) (Cmax)(From the time of infusion through Day 90 postinfusion.)
- Area Under the Curve to Infinity (AUC[0-inf])(From the time of infusion through Day 90 postinfusion.)
- Elimination Rate Constant(From the time of infusion through Day 90 postinfusion.)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety Study of Mesenchymal Precursor Cells in Type 2 DiabetesType 2 DiabetesNCT01576328Mesoblast, Ltd.61
已完成
1 期
A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)Acute Ischemic StrokeNCT04608838Teijin Pharma Limited79
已完成
3 期
A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)Colorectal SurgeryNCT00090272Merck Sharp & Dohme LLC952
进行中（未招募）
1 期
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)Lysosomal Storage DiseasesPompe Disease (Late-onset)Glycogen Storage Disease Type 2Glycogen Storage Disease Type IILOPDAcid Maltase DeficiencyPompe DiseaseNCT04093349Spark Therapeutics, Inc.4
终止
2 期
Phase IIa Clinical Study of N-Rephasin® SAL200Staphylococcus Aureus BacteremiaAnti-Bacterial AgentsNCT03089697Intron Biotechnology, Inc.25